Thomas MacVittie, MS, PhD
Dr. MacVittie is a Professor of Radiation Oncology and Pathology at the University of Maryland School of Medicine and is recognized internationally as an expert on the effects of radiation on the hematopoietic and gastrointestinal systems in non-human primates and their treatment. His early work demonstrated the efficacy of medical management (supportive care) and hematopoietic growth factors on increasing survival in lethally irradiated large animal models. The MacVittie group’s database demonstrating the effect of cytokines on enhancing survival and recovery of hematopoiesis serves as the focal point for current efforts to design the first pivotal trials under the FDA’s animal rule to determine the treatment efficacy of candidate drugs/biologics for final FDA approval. Dr. MacVittie has served as an advisor to the World Health Organization (WHO) Collaborating Centers in Radiation Emergency Medical Preparedness and Assistance and the International Council on Radiation Protection and as a member of North Atlantic Treaty Organization (NATO) Radiation Research Study Groups. He is a member of the Centers for Disease Control and Prevention (CDC) Strategic National Stockpile Radiation Working Group, the International Association of Radiopathology, the American Society of Hematology, the International Society of Experimental Hematology, Radiation Research and the International Society of Cellular Therapy. Dr. MacVittie is a member of the editorial board of the journal Stem Cells and serves as an ad hoc reviewer for numerous journals and NIH/National Institute of Allergy and Infectious Diseases (NIAID) and Department of Defense (DoD) grants and contracts. He was also a consultant for the International Atomic Energy Agency (IAEA) and Canadian Defense Research Establishment and also served on the first National Biodefense Science Board Federal Advisory Committee at the invitation of the Secretary, U.S. Department of Health and Human Services. He has more than 150 peer-reviewed publications.